Search research articles
Contact Us
Filters
Showing results (21-30 of 38) with videos related to
Page
of 4
Sort By:
Cancer Biology & Therapy
|
April 14, 2018
CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients
Nicholas C Nicolaides, Charles Schweizer, Elizabeth B Somers, et al.
Mabs
|
May 26, 2017
Engineering humanized antibody framework sequences for optimal site-specific conjugation of cytotoxins
Jared L Spidel, Earl F Albone, Xin Cheng, et al.
Cytogenetic and Genome Research
|
October 18, 2017
FCGR2A and FCGR3A Genotypes Correlate with Farletuzumab Response in Patients with First-Relapsed Ovarian Cancer Exhibiting Low CA125
Wenquan Wang, Elizabeth B Somers, Erin N Ross, et al.
Cancer Biology & Therapy
|
April 11, 2017
Generation of therapeutic immunoconjugates via Residue-Specific Conjugation Technology (RESPECT) utilizing a native cysteine in the light chain framework of Oryctolagus cuniculus
Earl F Albone, Jared L Spidel, Xin Cheng, et al.
Cancer Biology & Therapy
|
February 21, 2014
Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model
Chunsheng Li, Ann-Marie Chacko, Jia Hu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 15, 2014
Development of 124I immuno-PET targeting tumor vascular TEM1/endosialin
Ann-Marie Chacko, Chunsheng Li, Madhura Nayak, et al.
Genomics
|
April 29, 2017
Correlation of FCGRT genomic structure with serum immunoglobulin, albumin and farletuzumab pharmacokinetics in patients with first relapsed ovarian cancer
Daniel J O'Shannessy, Katie Bendas, Charles Schweizer, et al.
Oncotarget
|
September 9, 2017
Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-γ receptor engagement
James Bradford Kline, Rina P Kennedy, Earl Albone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 16, 2014
A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors
Luis A Diaz, Christina M Coughlin, Susan C Weil, et al.
Molecular Pharmaceutics
|
August 23, 2017
Improved Intraoperative Detection of Ovarian Cancer by Folate Receptor Alpha Targeted Dual-Modality Imaging
Marlène C H Hekman, Otto C Boerman, Desirée L Bos, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 38) with videos related to
Sort By:
Page
of 4
Cancer Biology & Therapy
|
April 14, 2018
CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients
Nicholas C Nicolaides, Charles Schweizer, Elizabeth B Somers, et al.
Mabs
|
May 26, 2017
Engineering humanized antibody framework sequences for optimal site-specific conjugation of cytotoxins
Jared L Spidel, Earl F Albone, Xin Cheng, et al.
Cytogenetic and Genome Research
|
October 18, 2017
FCGR2A and FCGR3A Genotypes Correlate with Farletuzumab Response in Patients with First-Relapsed Ovarian Cancer Exhibiting Low CA125
Wenquan Wang, Elizabeth B Somers, Erin N Ross, et al.
Cancer Biology & Therapy
|
April 11, 2017
Generation of therapeutic immunoconjugates via Residue-Specific Conjugation Technology (RESPECT) utilizing a native cysteine in the light chain framework of Oryctolagus cuniculus
Earl F Albone, Jared L Spidel, Xin Cheng, et al.
Cancer Biology & Therapy
|
February 21, 2014
Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model
Chunsheng Li, Ann-Marie Chacko, Jia Hu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 15, 2014
Development of 124I immuno-PET targeting tumor vascular TEM1/endosialin
Ann-Marie Chacko, Chunsheng Li, Madhura Nayak, et al.
Genomics
|
April 29, 2017
Correlation of FCGRT genomic structure with serum immunoglobulin, albumin and farletuzumab pharmacokinetics in patients with first relapsed ovarian cancer
Daniel J O'Shannessy, Katie Bendas, Charles Schweizer, et al.
Oncotarget
|
September 9, 2017
Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-γ receptor engagement
James Bradford Kline, Rina P Kennedy, Earl Albone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 16, 2014
A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors
Luis A Diaz, Christina M Coughlin, Susan C Weil, et al.
Molecular Pharmaceutics
|
August 23, 2017
Improved Intraoperative Detection of Ovarian Cancer by Folate Receptor Alpha Targeted Dual-Modality Imaging
Marlène C H Hekman, Otto C Boerman, Desirée L Bos, et al.
Page
of 4